Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 241

1.

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.

Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP.

Cell. 2005 Apr 22;121(2):179-93.

2.

Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.

Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C, Pandolfi PP.

Cancer Res. 2007 Aug 1;67(15):7106-12.

3.

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.

PMID:
19539245
4.

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.

Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R.

J Cell Biol. 2002 Oct 28;159(2):217-24. Epub 2002 Oct 28.

5.

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.

Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13489-94. Epub 2004 Sep 1.

6.

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.

Inoki K, Li Y, Zhu T, Wu J, Guan KL.

Nat Cell Biol. 2002 Sep;4(9):648-57.

PMID:
12172553
7.

Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.

Chan JA, Zhang H, Roberts PS, Jozwiak S, Wieslawa G, Lewin-Kowalik J, Kotulska K, Kwiatkowski DJ.

J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42.

PMID:
15624760
8.

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.

Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, Blenis J.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6. Epub 2002 Sep 23.

9.

Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.

Robb VA, Astrinidis A, Henske EP.

Mod Pathol. 2006 Jun;19(6):839-46. Erratum in: Mod Pathol. 2006 Jun;19(6):889.

10.

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Inoki K, Li Y, Xu T, Guan KL.

Genes Dev. 2003 Aug 1;17(15):1829-34. Epub 2003 Jul 17.

11.

Regulation of TSC2 by 14-3-3 binding.

Li Y, Inoki K, Yeung R, Guan KL.

J Biol Chem. 2002 Nov 22;277(47):44593-6. Epub 2002 Oct 2.

12.

Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.

Kwiatkowski DJ.

Cancer Biol Ther. 2003 Sep-Oct;2(5):471-6. Review.

PMID:
14614311
13.
14.
15.

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL.

Genes Chromosomes Cancer. 2005 Mar;42(3):213-27.

PMID:
15578690
16.

Heterozygosity for the tuberous sclerosis complex (TSC) gene products results in increased astrocyte numbers and decreased p27-Kip1 expression in TSC2+/- cells.

Uhlmann EJ, Apicelli AJ, Baldwin RL, Burke SP, Bajenaru ML, Onda H, Kwiatkowski D, Gutmann DH.

Oncogene. 2002 Jun 6;21(25):4050-9.

17.

Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors.

Kenerson HL, Aicher LD, True LD, Yeung RS.

Cancer Res. 2002 Oct 15;62(20):5645-50.

18.

Tuberin phosphorylation regulates its interaction with hamartin. Two proteins involved in tuberous sclerosis.

Aicher LD, Campbell JS, Yeung RS.

J Biol Chem. 2001 Jun 15;276(24):21017-21. Epub 2001 Apr 4.

19.

Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex.

Hoogeveen-Westerveld M, Ekong R, Povey S, Mayer K, Lannoy N, Elmslie F, Bebin M, Dies K, Thompson C, Sparagana SP, Davies P, van Eeghen AM, Thiele EA, van den Ouweland A, Halley D, Nellist M.

Hum Mutat. 2013 Jan;34(1):167-75. doi: 10.1002/humu.22202. Epub 2012 Oct 11. Erratum in: Hum Mutat. 2013 Feb;34(2):408-10. van Eeghen, Agnies M [added]; Thiele, Elizabeth A [added].

PMID:
22903760
20.

Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation.

Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH.

Glia. 2004 Aug 1;47(2):180-8.

PMID:
15185396

Supplemental Content

Support Center